Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• The east Texas bleeding disorder is a rare hemorrhagic condition with an unknown molecular basis.
• Coagulation factor V (FV) plays a critical role in hemostasis, and its dysregulation can lead to bleeding disorders.
• Tissue factor pathway inhibitor-α (TFPIα) is a key regulator of the extrinsic coagulation pathway.

Purpose of the Study:

• To elucidate the genetic and molecular mechanisms underlying the east Texas bleeding disorder.
• To identify the specific genetic mutation responsible for the observed bleeding phenotype.
• To characterize the functional consequences of the identified genetic defect on coagulation.

Main Methods:

• Genetic sequencing of affected individuals to identify mutations in coagulation factor genes.
• Analysis of gene expression and alternative splicing in patient-derived samples.
• Characterization of the novel FV isoform using molecular and biochemical assays.

Main Results:

• A mutation in exon 13 of the coagulation F5 gene was identified in affected individuals.
• This mutation leads to the expression of a previously unrecognized FV isoform, termed FV-short, due to alternative splicing.
• FV-short results in a 10-fold increase in circulating TFPIα levels, causing a significant anticoagulant effect and hemorrhagic diathesis.

Conclusions:

• The east Texas bleeding disorder is caused by a specific mutation in the F5 gene leading to the FV-short isoform.
• The FV-short isoform dysregulates the coagulation cascade by increasing TFPIα levels, resulting in a bleeding tendency.
• This study provides a molecular explanation for a rare bleeding disorder and highlights the complex regulation of hemostasis.